Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.

4894 | T

Overview

Corporate Details

ISIN(s):
JP3266030000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cuorips Inc. is a regenerative medicine company engaged in the research, development, manufacturing, and commercialization of cell-based therapeutic products. The company specializes in advanced technologies involving induced pluripotent stem (iPS) cells. Its flagship development is the world's first iPS cell-derived cardiomyocyte sheet, a novel treatment targeting severe heart failure. In addition to its own product pipeline, Cuorips is involved in optimizing manufacturing and quality processes and offers contract development services to contribute to the broader advancement of medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:13
Registration Form
確認書
Japanese 8.1 KB
2025-11-13 08:07
Interim Report
半期報告書-第10期(2025/04/01-2026/03/31)
Japanese 199.3 KB
2025-06-25 08:39
Post-Annual General Meeting Information
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 08:38
Governance Information
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
Annual Report
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 02:24
Interim Report
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
Governance Information
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:36
Annual Report
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-02-13 07:36
Quarterly Report
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
Report Publication Announcement
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cuorips Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.